Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol.

van der Linden; H Marieke; Maria Grazia Valsecchi; De Lorenzo Paola; Gritta Janka-Schaub; Gritta Janka; Thierry M Leblanc; Maria Felice; Biondi Andrea; Myriam Campbell; Ian Hann; Jeffrey E Rubnitz; Jan Stary; Tomasz Szczepanski; Ajay Vora; Alina Ferster; Liisa Hovi; Lewis B Silverman; Rob Pieters

Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol.

Standard

Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol. / Linden, van der; Marieke, H; Valsecchi, Maria Grazia; Paola, De Lorenzo; Janka-Schaub, Gritta; Janka, Gritta; Leblanc, Thierry M; Felice, Maria; Andrea, Biondi; Campbell, Myriam; Hann, Ian; Rubnitz, Jeffrey E; Stary, Jan; Szczepanski, Tomasz; Vora, Ajay; Ferster, Alina; Hovi, Liisa; Silverman, Lewis B; Pieters, Rob.

In: BLOOD, Vol. 114, No. 18, 18, 2009, p. 3764-3768.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Linden, VD, Marieke, H, Valsecchi, MG, Paola, DL, Janka-Schaub, G, Janka, G, Leblanc, TM, Felice, M, Andrea, B, Campbell, M, Hann, I, Rubnitz, JE, Stary, J, Szczepanski, T, Vora, A, Ferster, A, Hovi, L, Silverman, LB & Pieters, R 2009, 'Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol.', BLOOD, vol. 114, no. 18, 18, pp. 3764-3768. <http://www.ncbi.nlm.nih.gov/pubmed/19657114?dopt=Citation>

APA

Linden, V. D., Marieke, H., Valsecchi, M. G., Paola, D. L., Janka-Schaub, G., Janka, G., Leblanc, T. M., Felice, M., Andrea, B., Campbell, M., Hann, I., Rubnitz, J. E., Stary, J., Szczepanski, T., Vora, A., Ferster, A., Hovi, L., Silverman, L. B., & Pieters, R. (2009). Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol. BLOOD, 114(18), 3764-3768. [18]. http://www.ncbi.nlm.nih.gov/pubmed/19657114?dopt=Citation

Vancouver

Linden VD, Marieke H, Valsecchi MG, Paola DL, Janka-Schaub G, Janka G et al. Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol. BLOOD. 2009;114(18):3764-3768. 18.

Bibtex

@article{20e84d394cc0479dad8dcc29c55a896d,

title = "Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol.",

abstract = "Acute lymphoblastic leukemia (ALL) diagnosed in the first month of life (congenital ALL) is very rare. Although congenital ALL is often assumed to be fatal, no studies have been published on outcome except for case reports. The present study reports the outcome of 30 patients with congenital ALL treated with the uniform Interfant-99 protocol, a hybrid regimen combining ALL treatment with elements designed for treatment of acute myeloid leukemia. Congenital ALL was characterized by a higher white blood cell count and a strong trend for higher incidence of MLL rearrangements and CD10-negative B-lineage ALL compared with older infants. Induction failure rate was 13% and not significantly different from that in older infants (7%, P = .14), but relapse rate was significantly higher in congenital ALL patients (2-year cumulative incidence [SE] was 60.0 [9.3] vs 34.2 [2.3], P <.001). Two-year event-free survival and survival of congenital ALL patients treated with this protocol was 20% (SE 9.1%). Early death in complete remission and treatment delays resulting from toxicity were not different. The survival of 17% after last follow-up, combined with a toxicity profile comparable with that in older infants, justifies treating congenital ALL with curative intent. This trial was registered at www.clinicaltrials.gov as no. NCT 00015873, and at www.controlled-trials.com as no. ISRCTN24251487.",

author = "Linden, {van der} and H Marieke and Valsecchi, {Maria Grazia} and Paola, {De Lorenzo} and Gritta Janka-Schaub and Gritta Janka and Leblanc, {Thierry M} and Maria Felice and Biondi Andrea and Myriam Campbell and Ian Hann and Rubnitz, {Jeffrey E} and Jan Stary and Tomasz Szczepanski and Ajay Vora and Alina Ferster and Liisa Hovi and Silverman, {Lewis B} and Rob Pieters",

year = "2009",

language = "Deutsch",

volume = "114",

pages = "3764--3768",

journal = "BLOOD",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "18",

}

RIS

TY - JOUR

T1 - Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol.

AU - Linden, van der

AU - Marieke, H

AU - Valsecchi, Maria Grazia

AU - Paola, De Lorenzo

AU - Janka-Schaub, Gritta

AU - Janka, Gritta

AU - Leblanc, Thierry M

AU - Felice, Maria

AU - Andrea, Biondi

AU - Campbell, Myriam

AU - Hann, Ian

AU - Rubnitz, Jeffrey E

AU - Stary, Jan

AU - Szczepanski, Tomasz

AU - Vora, Ajay

AU - Ferster, Alina

AU - Hovi, Liisa

AU - Silverman, Lewis B

AU - Pieters, Rob

PY - 2009

Y1 - 2009

N2 - Acute lymphoblastic leukemia (ALL) diagnosed in the first month of life (congenital ALL) is very rare. Although congenital ALL is often assumed to be fatal, no studies have been published on outcome except for case reports. The present study reports the outcome of 30 patients with congenital ALL treated with the uniform Interfant-99 protocol, a hybrid regimen combining ALL treatment with elements designed for treatment of acute myeloid leukemia. Congenital ALL was characterized by a higher white blood cell count and a strong trend for higher incidence of MLL rearrangements and CD10-negative B-lineage ALL compared with older infants. Induction failure rate was 13% and not significantly different from that in older infants (7%, P = .14), but relapse rate was significantly higher in congenital ALL patients (2-year cumulative incidence [SE] was 60.0 [9.3] vs 34.2 [2.3], P <.001). Two-year event-free survival and survival of congenital ALL patients treated with this protocol was 20% (SE 9.1%). Early death in complete remission and treatment delays resulting from toxicity were not different. The survival of 17% after last follow-up, combined with a toxicity profile comparable with that in older infants, justifies treating congenital ALL with curative intent. This trial was registered at www.clinicaltrials.gov as no. NCT 00015873, and at www.controlled-trials.com as no. ISRCTN24251487.

AB - Acute lymphoblastic leukemia (ALL) diagnosed in the first month of life (congenital ALL) is very rare. Although congenital ALL is often assumed to be fatal, no studies have been published on outcome except for case reports. The present study reports the outcome of 30 patients with congenital ALL treated with the uniform Interfant-99 protocol, a hybrid regimen combining ALL treatment with elements designed for treatment of acute myeloid leukemia. Congenital ALL was characterized by a higher white blood cell count and a strong trend for higher incidence of MLL rearrangements and CD10-negative B-lineage ALL compared with older infants. Induction failure rate was 13% and not significantly different from that in older infants (7%, P = .14), but relapse rate was significantly higher in congenital ALL patients (2-year cumulative incidence [SE] was 60.0 [9.3] vs 34.2 [2.3], P <.001). Two-year event-free survival and survival of congenital ALL patients treated with this protocol was 20% (SE 9.1%). Early death in complete remission and treatment delays resulting from toxicity were not different. The survival of 17% after last follow-up, combined with a toxicity profile comparable with that in older infants, justifies treating congenital ALL with curative intent. This trial was registered at www.clinicaltrials.gov as no. NCT 00015873, and at www.controlled-trials.com as no. ISRCTN24251487.

M3 - SCORING: Zeitschriftenaufsatz

VL - 114

SP - 3764

EP - 3768

JO - BLOOD

JF - BLOOD

SN - 0006-4971

IS - 18

M1 - 18

ER -